Three doses of Pfizer vaccine provides ‘strong’ immunity for children 6 months to 5 years old, says pharmaceutical company
Three doses of a child-size Pfizer vaccine is not just safe but effective for children between the ages of 6 months and 5 years old, the company said Monday.
Pfizer plans to submit its trial data to the Food and Drug Administration this week as parents of young children push frantically for protection for their tots.
The trial, which used 1,678 children, injected a third dose of a 1/10th strength jab while Omicron was at its peak. A month later, antibody levels showed a similar immune response as 16-to-25-year-olds with two doses, Pfizer said.
The shot was “well tolerated” and most side effects were “mild or moderate.”
Video: Pfizer to submit Covid vaccine data for kids under age 5 this week (CNBC)
-
Credit Suisse has been losing its status as an attractive platform for wealth managers, analyst says
CNBC -
Credit Suisse CEO says 'completely unacceptable' numbers show why overhaul is needed
CNBC -
Disney's 7,000 jobs cuts were 'necessary,' analyst says
CNBC -
We expect most emerging markets will start decreasing rates this year: Wealth management firm
CNBC -
Expect to see better earnings from Straits Times Index constituents: Singapore Exchange
CNBC -
Microsoft is 'unbelievably good' at enterprise software, Jefferies says
CNBC -
Many Chinese tech names could see 50% to 70% upside, says investment firm
CNBC -
India's largest lender discusses exposure to Adani
CNBC -
Marcos Jr.'s Japan trip is his 'most important' foreign visit yet, lecturer says
CNBC -
Toyota is behind the curve in the electric vehicle market, says auto consultancy
CNBC -
Jim Cramer says he's 'intrigued' by these 10 top performing stocks
CNBC -
Cramer's lightning round: Vimeo is not a buy
CNBC -
Mattel CEO on consumer demand expectations for 2023
CNBC -
Sec. Raimondo on the possibility of teaming up with India to produce semiconductor chips
CNBC -
AGCO CEO on global crop prices and demand for farming technology
CNBC -
Jim Cramer says market bears are in denial
CNBC
-
Credit Suisse has been losing its status as an attractive platform for wealth managers, analyst says Johann Scholtz, equity analyst at Morningstar, discusses Credit Suisse's fourth-quarter net loss of 1.4 billion Swiss francs ($1.51 billion). CNBC
-
Credit Suisse CEO says 'completely unacceptable' numbers show why overhaul is needed Credit Suisse CEO Ulrich Koerner discusses the bank's fourth-quarter and 2022 full-year earnings, along with the embattled Swiss bank's ongoing transformation project. CNBC
-
Disney's 7,000 jobs cuts were 'necessary,' analyst says Rick Munarriz of Motley Fool discusses Disney's restructuring plans and $5.5 billion in cost-cutting. CNBC
The first two doses in the trial were given three weeks apart and the final shot came at least two months later.
© Rogelio V. Solis
Children under 5 are still not eligible for a COVID-19 vaccine.
Children under 5 are still not eligible for a COVID-19 vaccine. (Rogelio V. Solis/)
“Our COVID-19 vaccine has been studied in thousands of children and adolescents, and we are pleased that our formulation for the youngest children, which we carefully selected to be one-tenth of the dose strength for adults, was well tolerated and produced a strong immune response,” Albert Bourla, the chairman and CEO at Pfizer, said in a statement.
“These topline safety, immunogenicity and efficacy data are encouraging, and we look forward to soon completing our submissions to regulators globally with the hope of making this vaccine available to younger children as quickly as possible, subject to regulatory authorization.”
Children under the age of 5 are the only group of the population not yet eligible for a COVID-19 vaccine. Moderna submitted its own data to the FDA in late April.
